Protocols

Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx

→ San Diego-based Imprimis has set up a new subsidiary to pursue the development of new drugs for eye diseases. And the company has tapped Kamran Hosseini to run the operation — Surface Pharmaceuticals — as the CEO.

The Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation are helping fund a new combination therapy for Alzheimer’s by Amylyx Pharmaceuticals. Their $1.85 million grant will support a small Phase II study with 50 patients, who will be treated with AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid.

→ Framingham, MA-based Alzheon says that it has gained the FDA’s fast track designation for the Alzheimer’s drug ALZ-801.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 32,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Director, Financial Planning and Analysis
Molecular Templates Austin, TX
Manufacturing Associate – Downstream
Molecular Templates Austin, TX
Senior Statistician
Koneksa Health New York, NY

Visit Endpoints Careers ->